DCAL.NS

Dishman Carbogen Amcis Limited

NSEHealthcare

₹196.10

▲ +4.45%+₹8.35 today

₹0.00₹0.00

Ask Warren

Open

₹0.00

Prev close

₹187.75

Day range

₹0 – ₹0

52W range

₹128.5 – ₹321.95

Volume

18.5L

Avg vol (20D)

4.1L

Mkt cap

₹3,081.41Cr

P/E TTM

31.6×

Trade Dishman Carbogen Amcis Limited with Artha

Company Metrics

Revenue (ttm)₹2931.90 Cr

Net Income (ttm)₹0.00

Shares Out15.68 Cr

EPS (ttm)

Forward PE

Dividend

Ex-Dividend DateInvalid Date

Trading Metrics

Beta0.62

About DCAL.NS

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

IndustryBiotechnology

SectorHealthcare

Employees0

Stock ExchangeNSE

Ticker SymbolDCAL.NS

Websitehttps://imdcal.com

DCAL.NS · NSE

Financial Performance

In 2026, Dishman Carbogen Amcis Limited's revenue was ₹2931.90 Cr, an increase of +18.90% compared to the previous year. Earnings were ₹0.00, an decrease of +49.50%.

Revenue (2026)

₹2931.90 Cr

↗+18.90% YoY

Earnings (2026)

₹0.00

↘-49.50% YoY

Year-over-Year Growth

Revenue

+18.90%

Earnings

-49.50%

News

Save watchlists across devicesSet price alerts that buzz your phoneConnect Zerodha for one-tap trades

Create free account